Current Report Filing (8-k)
April 24 2020 - 2:57PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
____________________________________________________________
Date of Report (Date of earliest event reported):
April 16, 2020
RASNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada
|
|
333- 191083
|
|
39-2080103
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
|
|
|
|
420 Lexington Avenue, Suite 2525,
New York, NY
|
|
10170
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: 646-396-4087
(Former name or former address, if changed
since last report)
Copies to:
Jeffrey Fessler, Esq.
Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, New York 10112
Telephone: (212) 653-8700
Facsimile: (212) 653-8701
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this
chapter). Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
Item 1.01 Entry into a Material Definitive Agreement.
On April 16, 2020, Rasna Therapeutics, Inc.
(the “Company”) entered into an asset purchase agreement with Tiziana Life Sciences plc (“Tiziana”) pursuant
to which the Company agreed to sell all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin
D (Act D; a.k.a. Dactinomycin) to Tiziana in exchange for an upfront payment of $120,000 and milestone payments of up to an aggregate
$630,000.
The foregoing information is a summary of the
asset purchase agreement, is not complete, and is qualified in its entirety by reference to the full text of such agreement, a
copy of which will be attached as an exhibit to the Company’s Quarterly Report on Form 10-Q for the three months ended
March 31, 2020. A copy of the press release announcing the transaction is attached hereto as Exhibit 99.1.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: April 24, 2020
|
RASNA THERAPEUTICS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Tiziano Lazzaretti
|
|
|
|
Name: Tiziano Lazzaretti
|
|
|
|
Title: Chief Financial Officer
|
|
|
|
|
|
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Sep 2023 to Sep 2024